Compare · BTAI vs NBSE
BTAI vs NBSE
Side-by-side comparison of BioXcel Therapeutics Inc. (BTAI) and NeuBase Therapeutics Inc. (NBSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTAI and NBSE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NBSE is the larger of the two at $44.8M, about 1.3x BTAI ($34.1M).
- BTAI has hit the wire 6 times in the past 4 weeks while NBSE has been quiet.
- BTAI has more recent analyst coverage (12 ratings vs 0 for NBSE).
- Company
- BioXcel Therapeutics Inc.
- NeuBase Therapeutics Inc.
- Price
- $1.09-2.24%
- $0.38-3.32%
- Market cap
- $34.1M
- $44.8M
- 1M return
- -9.92%
- -
- 1Y return
- -43.81%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 0
- Recent ratings
- 12
- 0
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
NeuBase Therapeutics Inc.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Latest BTAI
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
- Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)
- Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)
- Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)
- CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)
- SEC Form 144 filed by BioXcel Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Latest NBSE
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by NeuBase Therapeutics Inc.
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- SEC Form DEFA14A filed by NeuBase Therapeutics Inc.
- 12 Health Care Stocks Moving In Friday's After-Market Session
- NeuBase Therapeutics Expects Trading In Co's Common Stock Will Be Suspended Upon Opening Of Business On May 13
- On May 2, Nasdaq Notified NeuBase Therapeutics Inc That It Has Not Regained Compliance With Minimum Bid Price Requirement
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Friday's After-Market Session